{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:08:11Z","timestamp":1765289291873,"version":"3.46.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ucl.2025.09.008","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T12:23:38Z","timestamp":1761654218000},"page":"89-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gleason Grade Group 1 Prostate Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Christopher P.","family":"Dall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle S.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam S.","family":"Kibel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander P.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ucl.2025.09.008_bib1","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.eururo.2023.09.002","article-title":"Uncovering the changing treatment landscape for low-risk prostate cancer in the USA from 2010 to 2020: insights from the national cancer data base","volume":"84","author":"Beatrici","year":"2023","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.008_bib2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41391-019-0157-y","article-title":"Contemporary national trends in prostate cancer risk profile at diagnosis","volume":"23","author":"Fletcher","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.008_bib3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41391-019-0175-9","article-title":"United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015","volume":"23","author":"Butler","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"8","key":"10.1016\/j.ucl.2025.09.008_bib4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/jama.2013.108415","article-title":"Overdiagnosis and overtreatment in cancer: an opportunity for improvement","volume":"310","author":"Esserman","year":"2013","journal-title":"JAMA"},{"issue":"27","key":"10.1016\/j.ucl.2025.09.008_bib5","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.22.00123","article-title":"Low-grade prostate cancer: time to stop calling it cancer","volume":"40","author":"Eggener","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ucl.2025.09.008_bib6","doi-asserted-by":"crossref","first-page":"e509","DOI":"10.1016\/S1470-2045(12)70388-1","article-title":"Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?","volume":"13","author":"Ahmed","year":"2012","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ucl.2025.09.008_bib7","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1001\/jamaoncol.2016.0386","article-title":"Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors","volume":"2","author":"Nikiforov","year":"2016","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.ucl.2025.09.008_bib8","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/jnci\/djad124","article-title":"Putting patients first to redefine prostate cancer classifications","volume":"115","author":"Nyame","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.ucl.2025.09.008_bib9","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.33621","article-title":"It\u2019s all in the name: does nomenclature for indolent prostate cancer impact management and anxiety?","volume":"127","author":"Hudnall","year":"2021","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.008_bib10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0022-5347(17)63039-8","article-title":"The histology and prognosis of prostatic cancer","volume":"97","author":"Mellinger","year":"1967","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.008_bib11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0022-5347(17)59889-4","article-title":"Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging","volume":"111","author":"Gleason","year":"1974","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.008_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2559.2011.04003.x","article-title":"Gleason grading: past, present and future","volume":"60","author":"Delahunt","year":"2012","journal-title":"Histopathology"},{"issue":"2 Pt 2","key":"10.1016\/j.ucl.2025.09.008_bib13","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0022-5347(02)80309-3","article-title":"Veterans administration cooperative urological research group. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. 1974","volume":"167","author":"Gleason","year":"2002","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.008_bib14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0046-8177(92)90108-F","article-title":"Histologic grading of prostate cancer: a perspective","volume":"23","author":"Gleason","year":"1992","journal-title":"Hum Pathol"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.008_bib15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.eururo.2006.02.006","article-title":"Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study","volume":"49","author":"Zlotta","year":"2006","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.008_bib16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00000478-200004000-00001","article-title":"Gleason score 2\u20134 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made","volume":"24","author":"Epstein","year":"2000","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.008_bib17","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.008_bib18","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/bju.14656","article-title":"Are historical studies relevant in the setting of grade migration?","volume":"123","author":"Szymaniak","year":"2019","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.008_bib19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.juro.2007.08.125","article-title":"The will rogers phenomenon in urological oncology","volume":"179","author":"Gofrit","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.008_bib20","doi-asserted-by":"crossref","DOI":"10.1097\/PAS.0000000000002425","article-title":"Genitourinary pathology society and international society of urological pathology white paper on defining indolent prostate cancer","author":"Shah","year":"2025","journal-title":"Am J Surg Pathol"},{"issue":"32","key":"10.1016\/j.ucl.2025.09.008_bib21","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1038\/onc.2012.541","article-title":"Cells of origin for cancer: an updated view from prostate cancer","volume":"32","author":"Xin","year":"2013","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.008_bib22","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.3390\/curroncol29030152","article-title":"Adenoid cystic carcinoma\/basal cell carcinoma of the prostate: overview and update on rare prostate cancer subtypes","volume":"29","author":"Cozzi","year":"2022","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.008_bib23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ajpath.2022.09.010","article-title":"Genomic characterization of prostatic basal cell carcinoma","volume":"193","author":"Low","year":"2023","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.008_bib24","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/(SICI)1097-0142(19960715)78:2<376::AID-CNCR32>3.0.CO;2-R","article-title":"Workgroup 5: assessment of prostate carcinoma in core needle biopsy--Definition of minimal criteria for the diagnosis of cancer in biopsy material","volume":"78","author":"Algaba","year":"1996","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ucl.2025.09.008_bib25","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030411","article-title":"Histopathology of prostate cancer","volume":"7","author":"Humphrey","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"S1","key":"10.1016\/j.ucl.2025.09.008_bib26","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1038\/modpathol.2017.136","article-title":"Benign mimics of prostatic adenocarcinoma","volume":"31","author":"Trpkov","year":"2018","journal-title":"Mod Pathol"},{"issue":"9\u201310","key":"10.1016\/j.ucl.2025.09.008_bib27","doi-asserted-by":"crossref","first-page":"339","DOI":"10.5489\/cuaj.4146","article-title":"One is the new six: the international society of urological pathology (ISUP) patient-focused approach to gleason grading","volume":"10","author":"Srigley","year":"2016","journal-title":"Can Urol Assoc J"},{"issue":"Supplement 4","key":"10.1016\/j.ucl.2025.09.008_bib28","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000003357.08","article-title":"MP80-08 clinical significance of extraprostatic extension in grade group 1 prostate cancer","volume":"209","author":"Rezaee","year":"2023","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.008_bib29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1158\/1055-9965.EPI-16-0237","article-title":"Perineural invasion and risk of lethal prostate cancer","volume":"26","author":"Zareba","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.008_bib30","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/PAT.0000000000000097","article-title":"Nationwide prevalence of lymph node metastases in gleason score 3 + 3 = 6 prostate cancer","volume":"46","author":"Liu","year":"2014","journal-title":"Pathology"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.008_bib31","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3892\/mco.2014.370","article-title":"Upgrading and upstaging in prostate cancer: from prostate biopsy to radical prostatectomy","volume":"2","author":"D\u2019Elia","year":"2014","journal-title":"Mol Clin Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.008_bib32","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/pros.24280","article-title":"Preoperative MRI PI-RADS scores are associated with prostate cancer upstaging on surgical pathology","volume":"82","author":"Pockros","year":"2022","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.008_bib33","doi-asserted-by":"crossref","first-page":"981","DOI":"10.37349\/etat.2024.00259","article-title":"Risk factors for gleason score upgrade from prostate biopsy to radical prostatectomy","volume":"5","author":"Smani","year":"2024","journal-title":"Explor Target Antitumor Ther"},{"issue":"3 Pt 1","key":"10.1016\/j.ucl.2025.09.008_bib34","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.juro.2016.08.095","article-title":"Risk of pathological upgrading and up staging among men with low risk prostate cancer varies by race: results from the national cancer database","volume":"197","author":"Maurice","year":"2017","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.008_bib35","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.juro.2016.08.091","article-title":"Molecular analysis of low grade prostate cancer using a genomic classifier of metastatic potential","volume":"197","author":"Klein","year":"2017","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.008_bib36","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/modpathol.2014.85","article-title":"PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy","volume":"28","author":"Lotan","year":"2015","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.ucl.2025.09.008_bib37","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/PAS.0b013e3182556dcd","article-title":"Do adenocarcinomas of the prostate with gleason score (GS) \u22646 have the potential to metastasize to lymph nodes?","volume":"36","author":"Ross","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.008_bib38","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/j.1464-410X.2006.06166.x","article-title":"Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng\/mL and biopsy gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy","volume":"97","author":"Weckermann","year":"2006","journal-title":"BJU Int"},{"issue":"21","key":"10.1016\/j.ucl.2025.09.008_bib39","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1200\/JCO.2008.20.4669","article-title":"Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?","volume":"27","author":"Stark","year":"2009","journal-title":"J Clin Oncol"},{"issue":"45","key":"10.1016\/j.ucl.2025.09.008_bib40","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/jncimonographs\/lgs041","volume":"2012","author":"Wilt","year":"2012","journal-title":"JNCI Monographs"},{"issue":"17","key":"10.1016\/j.ucl.2025.09.008_bib41","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ucl.2025.09.008_bib42","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.31015","article-title":"Long-term outcomes among men undergoing active surveillance for prostate cancer in Sweden","volume":"5","author":"Ventimiglia","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.008_bib43","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.euo.2024.07.003","article-title":"Has active surveillance for prostate cancer become safer? Lessons learned from a global clinical registry","volume":"8","author":"Bangma","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.008_bib44","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.008_bib45","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.ucl.2025.09.008_bib46","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/jnci\/djad108","article-title":"The influence of the \u201ccancer\u201d label on perceptions and management decisions for low-grade prostate cancer","volume":"115","author":"Berlin","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.008_bib47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s43058-024-00576-x","article-title":"Unpacking overuse of androgen deprivation therapy for prostate cancer to inform de-implementation strategies","volume":"5","author":"Skolarus","year":"2024","journal-title":"Implement Sci Commun"},{"key":"10.1016\/j.ucl.2025.09.008_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1073580","article-title":"Gleason 6 prostate cancer: that which cannot be named","volume":"12","author":"Burke","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ucl.2025.09.008_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.pecinn.2023.100165","article-title":"\u201cyour cancer is no longer considered cancer\u201d: psychological reactions to reclassification information and communication preferences","volume":"2","author":"Mindlis","year":"2023","journal-title":"PEC Innov"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.008_bib50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.008_bib51","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.juro.2015.01.126","article-title":"Gleason 6 prostate cancer: translating biology into population health","volume":"194","author":"Eggener","year":"2015","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.008_bib52","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/02813432.2020.1843826","article-title":"Psychosocial consequences of potential overdiagnosis in prostate cancer a qualitative interview study","volume":"38","author":"Nielsen","year":"2020","journal-title":"Scand J Prim Health Care"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.008_bib53","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1377\/hlthaff.2011.1062","article-title":"Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse","volume":"31","author":"Jacobs","year":"2012","journal-title":"Health Aff"},{"issue":"7","key":"10.1016\/j.ucl.2025.09.008_bib54","first-page":"1117","article-title":"Time trends and local variation in primary treatment of localized prostate cancer","volume":"28","author":"Cooperberg","year":"2010","journal-title":"J Clin Orthod"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.008_bib55","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","article-title":"Overdiagnosis and overtreatment of prostate cancer","volume":"65","author":"Loeb","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.008_bib56","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamainternmed.2024.5994","article-title":"Overtreatment of prostate cancer among men with limited longevity in the active surveillance era","volume":"185","author":"Daskivich","year":"2025","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ucl.2025.09.008_bib57","article-title":"MRI-Targeted prostate biopsy introduces grade inflation and overtreatment","author":"Batouche","year":"2024","journal-title":"medRxiv"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.008_bib58","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.eururo.2020.04.016","article-title":"Routine use of magnetic resonance imaging for early detection of prostate cancer is not justified by the clinical trial evidence","volume":"78","author":"Vickers","year":"2020","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.008_bib59","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ijrobp.2007.01.039","article-title":"Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer","volume":"68","author":"Lee","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.008_bib60","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.juro.2017.11.067","volume":"199","author":"Hassan","year":"2018","journal-title":"J Urol"},{"issue":"11","key":"10.1016\/j.ucl.2025.09.008_bib61","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/modpathol.2009.121","article-title":"TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma","volume":"22","author":"Albadine","year":"2009","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.008_bib62","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.eururo.2023.05.032","article-title":"Grade group 1 prostate cancers exhibit tumor-defining androgen receptor\u2013driven programs","volume":"84","author":"Linder","year":"2023","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.008_bib63","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.juro.2016.08.104","article-title":"Racial disparities in active surveillance for prostate cancer","volume":"197","author":"Krishna","year":"2017","journal-title":"J Urol"},{"issue":"27","key":"10.1016\/j.ucl.2025.09.008_bib64","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1200\/JCO.22.00926","article-title":"Renaming gleason score 6 prostate to noncancer: a flawed idea scientifically and for patient care","volume":"40","author":"Epstein","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ucl.2025.09.008_bib65","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1200\/JCO.2010.32.8112","article-title":"Active surveillance program for prostate cancer: an update of the johns hopkins experience","volume":"29","author":"Tosoian","year":"2011","journal-title":"J Clin Oncol"},{"issue":"202","key":"10.1016\/j.ucl.2025.09.008_bib66","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006408","article-title":"A molecular signature predictive of indolent prostate cancer","volume":"5","author":"Irshad","year":"2013","journal-title":"Sci Transl Med"},{"issue":"19","key":"10.1016\/j.ucl.2025.09.008_bib67","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.3390\/cancers13194771","article-title":"Molecular characterization of prostate cancers in the precision medicine era","volume":"13","author":"Giunta","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:04:32Z","timestamp":1765289072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014325000916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0094014325000916"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2025.09.008","relation":{},"ISSN":["0094-0143"],"issn-type":[{"type":"print","value":"0094-0143"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gleason Grade Group 1 Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2025.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}